Despite the many advances in clinical care for the treatment of acute myocardial infarction (MI) and heart failure (HF), cardiogenic shock (CS) survival remains unchanged at 40%. For MI patients alone, the 30-day mortality rate is 40-50%, and it has remained at this level for the last two decades.
Below are two novel trials exploring conditions of the aorta that are currently enrolling at Baylor Scott & White – The Heart Hospital Plano. These trials leverage our multi-disciplinary team approach, which brings Cardiothoracic and Vascular surgeons together in our TAA clinic for collaborative, simultaneous visits with each patient. This approach has proven time and again to better inform decisions surrounding patient care plans and help produce stronger outcomes.
Technology is constantly evolving, and disruptive innovation is pushing the boundaries of cardiothoracic therapeutics. The growing acceptance of less invasive transcatheter interventions, for example, has made it one of the more explored surgical modalities. This progressive technology in cardiothoracic surgery was underscored in many sessions at this year’s meeting of The Society of Thoracic Surgeons (STS) in San Diego.
Outcomes from Partner 3, a clinical trial evaluating transcatheter aortic valve replacement, or TAVR, compared to traditional surgical repair for low risk patients with aortic stenosis were recently published in The New England Journal of Medicine.
Baylor Scott & White The Heart Hospital – Plano is playing a key role in developing a first-of-its-kind wound imaging device equipped with artificial intelligence to noninvasively evaluate wounds and chronically ischemic limbs. The WISCR (Wound Imaging System to Collect Clinical References) study is collecting wound images and data to further develop the DeepView Wound Imaging System device.
